Latest News
-
UK to overhaul its antitrust system to drive growth
Britain wants to improve its competition regime. It has launched a formal consultation to see if it can be made "faster, predictable, and more proportionate". The government announced that it would speed up and simplify the anti-trust investigations, "working closely" with CMA (competition regulatory body) while maintaining its independence. It added that the consultation proposed changes to the way the CMA makes merger decisions and market investigations. This would ensure market remedies were regularly reviewed and businesses could be more certain about whether they will face merger controls. The CMA's decision-making independence will not be affected by these proposals, it was added. The CMA announced on Monday that they would review their historical interventions in order to determine if any of them were still needed to reduce the burden?of compliance. They identified 33 market'remedies' - 60 percent of all those already in place – that might no longer be necessary. The government has also announced that the state-owned bank for development will invest in Kraken Technologies 25 million pounds ($34million) as its largest direct investment, supporting the AI energy software company ahead of an eventual London listing. The government announced that the investment in Kraken, valued at $8.45billion after its spinoff from UK-based Octopus last year, follows reforms made to the British Business Bank mandate, allowing them to take larger, more risky stakes in important scale-ups. Peter Kyle, the business minister, said that Britain's most promising businesses have been looking abroad for support to help them grow. "We are cutting red tape and backing innovators who can really 'firepower'. According to a statement, The BBB, 'owned by the Government's Business Department but operatingly independent', will invest separately 50 million pounds in Epidarex Capital and IQ Capital. Kraken, a company that provides energy software to utilities, energy groups, and companies such as EDF, National Grid U.S., and Tokyo Gas, has 70,000,000 global customers. It "may list in London", the government said, following its demerger.
-
The Russian budget deficit in 2025 was 2.6% of the GDP, which is the highest level since 2020
The Finance Ministry announced on Monday that Russia had a budgetary deficit of 5.6 trillion roubles, or 2.6% of GDP, by 2025. This is the largest deficit in terms of percentage of GDP since 2020 and in roubles since 2006. In 2024, Russia's fiscal deficit was equal to 1.7% of its GDP. The?government increased the deficit target in 2025 from the initial?1.2 trillion Rubbles or 0.5% GDP due to the shrinking energy revenue and a strong Rouble. Budget revenues were 37.28 trillion rubles, down 7.5% on the original target. This was due to the 24% drop in oil and gas revenue, which reached its lowest level since 2020 despite the corporate profit and income tax increases. Budget spending, at 42.93 trillion rubles, was up 6.8% from 2024, and 3.5% more than the original?budget plan. Analysts doubt that the government will be able to meet its target, despite the fact that the government has raised the value added tax in order to keep the deficit this year at 1.6% of GDP.
-
Italian fashion great Valentino dead at 93
His foundation announced that Valentino Garavani, the Italian designer of fashion, died on Monday. Valentino, who is usually only known by his first name, was 93 years old and had Retired in 2008 Valentino, the founder of his eponymous label, was a pioneer in haute couture, who built a successful business empire, and also introduced to fashion a new color, the so-called "Valentino Red". The foundation posted on Instagram that "Valentino passed away today in a?his Roman home, surrounded by his loved ones." It added that the funeral would take place at 11am (1000 GMT) on Friday in Rome. Valentino, along with Giorgio Armani, Karl Lagerfeld and other great designers of an era when fashion was not a globalized industry dominated by marketing executives and accountants but rather a highly commercialized one. Lagerfeld The year 2019 has seen the death of many people. Armani Died in September. (Written by Alvise Armillini, edited by Gavin Jones).
-
Ghana's mining reforms could choke off investment, warns industry body
Ghana's main mining industry group said that changes in the country's tax and royalties terms could deter investment, and slow?output. Last week, it was reported that Africa's largest gold producer planned to cancel long-term mining investments stability agreements and double royalty payments under sweeping reforms. These changes will result in the termination of the?stability agreement with Newmont, AngloGold Ashanti, and Gold Fields. The mining regulator stated that the change was intended to increase state revenue and crackdown on companies abusing their licenses. The draft bill, which is expected to be presented to the parliament in March, proposes a royalty rate of 9%, rising to 12% when gold reaches $4,500 an ounce or more, about double the current range of 3% to 5%. Fear of Stalemated Projects, Lost Jobs In a statement released on Monday, the Chamber of Mines - which represents the 'big mining companies' - said that they supported the principle of a sliding scale royalty system, which would allow the government to earn more when gold prices are higher. It warned, however, that the current proposal could push Ghana up the global effective taxes curve and potentially cause projects to be halted or jobs to be lost. "We understand why a sliding scale is used, but it must be structured in a way that the government can secure sustainable revenues?while industry continues to grow and reinvest," said Chief Executive Kenneth Ashigbey. The current proposal fails to strike this balance. The chamber did not offer a "counterproposal". The Minerals Commission and the Lands and Natural Resources Ministry of Ghana did not respond immediately to comments. The chamber of commerce said that Ghana's large scale miners pay a 3% growth levy and a flat 3-5% royalty rate. Both are levied based on gross revenue, not profit, and include a 35% corporation income tax, an 8% dividends tax and a 10% state-free carried interest. It said that stability and development agreements need to be improved, but not repealed outright. The chamber welcomed the ongoing consultations between Ghana's Lands and Natural Resources Minister and stressed that a competitive, predictable fiscal regime is essential to sustaining investment. Maxwell Akalaare Adombila, Robbie Corey Boulet and Susan Fenton edited the report.
-
Gold and silver record highs amid Greenland dispute
Gold and silver reached record highs on Monday as investors fled to safety following the warnings from U.S. president Donald Trump about extra tariffs being imposed on certain European countries over a dispute regarding Greenland. By 12:05 pm, spot gold had risen 1.7% to $4672.49 per ounce. After reaching a record high of $4,689.39, ET (1705 GMT) was reached. U.S. Gold Futures for February Delivery increased 1.8% to $4677.70 per ounce. Trump threatened several European Allies on Saturday with an escalating series of tariffs unless the U.S. was allowed to "buy Greenland", intensifying a dispute about Denmark's vast Arctic Island. "When institutional or policy risks resurface the markets tend to'react quickly by reallocating towards safe-haven investments, with gold emerging once again as the preferred option," said XS.com senior analyst Linh Tran. Dollar fell after Trump's latest threats to raise tariffs prompted investors to seek out safe-haven currencies like gold, yen (Japan) and Swiss Franc. This was part of a broader risk-averse movement across all markets. Gold is more likely to do well in times of geopolitical or economic uncertainty and when interest rates are low. It has gained over 64% since 2025, and more than 8% in the first half of this year. Michelle Bowman, Vice Chair of the Federal Reserve for Supervision, said that the U.S. Central Bank should be prepared to lower interest rates if necessary due to a fragile and potentially weakening job market. The markets expect the Fed will hold rates at its meeting on January 27-28, but they are pricing in two 25 basis point rate cuts this year. Spot silver, which had previously reached a record-high of $94.61, has risen 5% to $94.41 per ounce. Since the beginning of the year, silver has increased by more than 32%. Citi Research analysts said they remain "tactically bullish" on precious metals. They set price targets for gold of $5,000 per ounce and silver at $100 per ounce in the next three month, citing the geopolitical tensions likely to continue to be high. Palladium increased 1.1%, to $1,819.99, while spot platinum rose 1.5%, to $2,362.65 per ounce.
-
Source: Canada could send a small contingent of troops into Greenland
A source familiar with the situation said that Canada was considering sending a small contingent of troops to Greenland in order to take part in NATO exercises. The first to report the news were CBC News and Globe and Mail. Source: Military officials have "presented" plans for the operation to government, and are "awaiting a decision by Prime Minister Mark Carney," said the source. The source requested anonymity due to the sensitive nature of the issue. Carney's office declined to comment. Carney is challenged by the threats of U.S. president Donald Trump to annex Canada. He wants to be on Trump's side, but also show solidarity with European allies. Carney, who spoke to reporters on Sunday in Doha, said: "We are concerned about this escalated situation. To be clear, we will always support the sovereignty and territorial integrity of countries, regardless of their geographical location." Last week, a small number of European countries sent military personnel to Greenland. Germany, France and Sweden have all said that they will be sending military personnel to start preparations for large drills in the second half of this year. Bill Berkrot edited the report by David Ljunggren.
-
Gold and silver record highs amid Greenland dispute
Gold and silver reached record highs on Monday as a result of a flight for safety following the warnings from U.S. president?Donald Trump about extra tariffs being imposed on certain European countries over a dispute?over Greenland. By 10:08 am, spot gold had risen 1.6% to $4.669.69 per ounce. After reaching a record high of $4,689.39 at 1508 GMT ET (Eastern Time), spot gold jumped 1.6% to $4,669.69 an ounce. U.S. Gold Futures for February Delivery increased 1.7% to $4.675 an ounce. Trump threatened several European Allies on Saturday with an escalating series of tariffs unless the U.S. was allowed to "buy Greenland", intensifying a dispute about Denmark's vast Arctic Island. "When institutional or policy risks resurface the markets tend to'react quickly by reallocating towards safe-haven investments, with gold emerging once again as the preferred option," said XS.com senior analyst Linh Tran. The dollar and stock markets fell after Trump's latest threats to raise tariffs prompted investors to flock towards'safe-haven' gold, Japanese yen, and Swiss francs in a risk-averse movement?across all markets. When interest rates are low and geopolitical or economic uncertainty is present, gold tends to perform well. It has gained over 64% since 2025, and more than 8% in the first half of this year. Michelle Bowman, Vice Chair of the Federal Reserve for Supervision, said that the U.S. Central Bank should be prepared to lower interest rates if necessary due to the fragile state of the job market. The markets expect the Fed to keep rates on hold at its meeting in January 27-28, but they are pricing in two rate cuts of 25 basis points or more this year. Silver spot also rose 4.4%, to $93.93 per ounce. This is after it reached a record high price of $94.10. Since the beginning of the year, silver has increased by more than 31%. Citi Research analysts remain tactically bullish, setting price targets for precious metals of $5,000 per ounce for Gold and $100 for Silver in the next 3 months. They cite geopolitical tensions likely to remain elevated in the short term. Palladium increased 1.2%, to $1,820.50, while spot platinum rose 2%, to $2,374.85 per ounce.
-
INTERVIEW: Saudi private sector to play a larger role in Vision 2030, Minister says at Davos
Economy Minister Faisal Al-Ibrahim said Saudi Arabia will hand over the scope of some Vision 2030 Projects to the private sector, as it adjusts timetables to avoid economic "overheating". Ibrahim stated in an interview conducted in Davos in Switzerland that the government was "agile" when managing its ambitious pipeline of development projects. He said some projects were rescoping, but maintained momentum in its Vision 2030 goals for economic transformation. Ibrahim stated on Monday that the private sector was ready and eager to participate. He added: "Recently some whole scopes of project were given to private sector with regulatory support and guidelines." The top oil exporter in the world is already more than half way through its Vision 2030 plan. This plan calls for government investments of hundreds of billions?of dollars to reduce its dependence on hydrocarbon revenues by investing in tourism and other sectors. Saudi Arabia is grappling with economic challenges and logistical limitations. This has led to delays and recalibrations in some of the landmark projects, such as NEOM - a futuristic desert city by the Red Sea. In?October, it was reported that the Kingdom is planning to divert its $925 billion sovereign fund from being focused on mega-projects in real estate. Saudi Arabia has heavily tapped the debt markets over the past few years, as oil prices, which are its main source of income have fallen below the levels needed to fund the program. Ibrahim said that the changes to 'the timeliness and scope of project were driven by multiple factors including inflation, import pressures, and economic overheating. He said that he did not want to "overheat" the economy. "We are very transparent." Ibrahim stated that he would not hesitate to say we had to delay, reschedule, or shift a project. If you believe that the project, "the brick and mortar"... is Vision 2030 then that could be a problem. The project exists to achieve a specific outcome. According to the Saudi budget for this year, 2026 marks the beginning of a “third phase” of Vision 2030,?signaling a shift from launching reforms in economics to maximising impact. Saudi Arabia’s non-oil sector now accounts for more than a fifth of its real GDP, and will continue to grow as the country strives to lessen its dependence on oil revenues. He said that the percentage of non-oil activity dependent on oil flow?has already fallen from approximately 90% to about 70% with the aim of driving this figure even lower. He said that most non-oil industries have experienced a steady growth rate of between 5-10% per year over the last five years. The ministry is expecting both the overall growth and non-oil to be strong, with a range of 4-5%, for the next three. Saudi Arabia is now focusing on hosting major international sporting events. The 2027 AFC Asian Cup and 2030 World Expo are the top priorities. Ibrahim stated that the organizers are studying Qatar's "successful 2022 World Cup tournament model, and consulting with Qatari officials. He said that the Qataris had been very helpful. (Reporting and writing by Samia Nakhoul and Dmitry Zhdannikov, Hadeel al Sayeghl, Editing by Alexander Smith).
Weight loss drug manufacturers are lining up to take advantage of a lucrative market, as the competition heats up
Novo Nordisk, Eli Lilly, and other pharmaceutical companies are in competition for the next generation of treatments for obesity.
In recent quarters, Eli Lilly’s Zepbound gained market share against Novo’s Wegovy -- a trend that led, in part to the Friday ouster of Novo CEO Lars Fruergaard Jorgensen.
Here is a list with weight loss drugs that are being developed by Novo, Lilly, and other companies in search of the next big treatment.
NOVO NORDISK
The Danish pharmaceutical company is developing several experimental weight loss drugs. These include a pill, a new-generation injection, called amycretin and a drug called CagriSema.
In an early stage trial last year, Novo's Amycretin, taken daily, led to a 13.1% weight reduction after only 12 weeks.
Early-mid-stage trials found that the shot version of amycretin caused patients to lose 22% of weight within 36 weeks.
CagriSema - touted as the potent successor of Wegovy - showed less-than-expected results in two late-stage studies. In one trial, the drug helped overweight patients reduce their weight by 22,7%. This was below Novo's expectation of 25%.
Novo intends to submit CagriSema to regulatory approval during the first quarter 2026.
Novo also has licensing agreements for drugs that are still in the testing stage, such as the $2 billion deal it signed with China's United Laboratories to develop a drug for weight loss called "triple G" which targets three hormones.
ELI LILLY
In a late-stage study, Lilly's weight-loss drug orforglipron has helped type 2 diabetics lose nearly 8% their body weight in 40 weeks.
This compares well with Novo's injectable drug Ozempic. Ozempic at the highest dosage for diabetic patients caused them to lose 6% of their weight.
Lilly plans to submit an application for orforglipron regulatory approval by the end the year.
Lilly reported that a mid-stage study of its next generation obesity drug candidate (a weekly injection retatrutide) led to a weight loss of as much as 24.2% in 48 weeks.
Lilly signed an agreement with China's Laekna biotech last year for the development of a drug to treat obesity that helps patients to lose weight and maintain muscle.
PFIZER
Pfizer stopped developing the experimental weight loss pill danuglipron in October after a patient who was undergoing a clinical trial experienced a potential drug-induced injury to the liver that resolved when the medication was discontinued.
In March, Roche acquired the rights to Zealand Pharma’s petrelintide obesity treatment in a possible deal worth up to $5,3 billion.
Carmot Therapeutics, a Swiss pharmaceutical company, acquired CT-388, an experimental drug for obesity, as part of a $2.7 billion purchase of Carmot Therapeutics that will take place in 2023. Carmot's injection, which is administered once a week, belongs to the same category as Lilly's Mounjaro or Zepbound.
The company announced last year that the early-stage trials of a second drug candidate purchased from Carmot had yielded positive outcomes.
In a year-long, mid-stage study, Amgen's MariTide drug helped obese patients lose up to 20% of body weight.
Amgen says that MariTide late-stage research will begin before the middle of this year.
Analysts say MariTide has similar weight loss benefits to Wegovy and Zepbound but slightly more side effects.
Merck signed an agreement in December worth up to $ 2 billion to license Hansoh Pharma’s oral experimental drug for treating obesity. Merck is now a late competitor to the race to provide a weight loss pill that can replace weekly injections.
The drug HS-10535 is a GLP-1 agonist similar to Wegovy or Zepbound.
ASTRAZENECA
AstraZeneca’s experimental weight loss pill, licensed from China’s Eccogene a year earlier for up to $ 2 billion, has been found safe and tolerable during an early-stage study in November 2024.
The drugmaker has announced that it is moving the once-daily pill AZD5004 into mid-stage clinical trials.
ALTIMMUNE
Altimmune's experimental weight-loss drug pemvidutide helped reduce weight on average by 15.6% and showed weight loss continued at the end treatment.
Some patients, however, experience mild to moderate nausea and vomiting.
VIKING THERAPEUTICS
Viking Therapeutics reported last year that its experimental drug VK2735 helped patients achieve a 14.7% weight loss mean after 13 weeks in a midstage study. The study enrolled 176 obese adults with at least 1 weight-related comorbidity.
The company reported that in November, nine patients who were given the highest dose of 100 milligrams lost an average of 8.2% body weight within 28 days of an early-stage study.
ZEALAND PHARMA
A Danish biotech company, Zealand Pharma, said that a high-dose of petrelintide (its weight-loss drug-candidate) helped reduce weight on average by 8.6% in an early stage study.
In August 2024, the company announced that it would begin talks with other pharmaceutical firms in the second half this year about potential partnerships for developing and commercializing petrelintide.
Therapeutics of Structure
Structure Therapeutics reported last year that its experimental oral weight loss drug reduced weight by an average of 6.2% at the end 12 weeks in a study conducted during mid-stage.
(source: Reuters)